Evaluating the Effectiveness of the Charlson Comorbidity Index in Predicting Immune Checkpoint Inhibitor-Related Adverse Events

Onur, İlknur Deliktaş; Mutlu, Emel; Sertesen, Elif; Önder, Tuğba; Duran, Ayşe Ocak; İnanç, Mevlüde

doi:10.2217/imt-2023-0270

Cited by 3 publications

(3 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Збільшення частоти коморбідності з віком асоціюється з моделями розвитку хвороб: екологічної, генетичної, акумуляційної, онтогенетичної [18][19][20]. Згідно з даними [21,37,56], коморбідність підвищується з 10 % у віці до 19 років до 80 % у осіб 80 років і старше. Найбільш поширеними коморбідними станами у пацієнтів похилого віку, які страждають на пухлини внутрішньочеревної локалізації, є гіпертонічна хвороба (74,8 %), ішемічна хвороба серця (68,3 %), аритмії (19,3 %), цукровий діабет (17,8 %), ХОЗЛ (5,9 %).…”

Section: рисунок 1 питома вага онкологічних пацієнтів з коморбідністю...unclassified

“…Найбільш поширеними коморбідними станами у пацієнтів похилого віку, які страждають на пухлини внутрішньочеревної локалізації, є гіпертонічна хвороба (74,8 %), ішемічна хвороба серця (68,3 %), аритмії (19,3 %), цукровий діабет (17,8 %), ХОЗЛ (5,9 %). У пацієнтів похилого та старечого віку відзначається незначна кореляційна залежність (коефіцієнт кореляції 0,9) між індексом коморбідності Чарлсон та тривалістю перебування у стаціонарі [22,37,56].…”

Section: рисунок 1 питома вага онкологічних пацієнтів з коморбідністю...unclassified

“…Крім того, завдяки покращенню методів діагностики, онкотераностики і терапії раку, неодмінно зростає кількість пацієнтів які живуть з онкологічним діагнозом, про що свідчать публікації 2023-2024 рр. [2,9,37,38,43,44,45]. І вони, швидше за все, відчуватимуть ті чи інші наслідки лікування раку в контексті інших супутніх захворювань.…”

Section: обговоренняunclassified

See 2 more Smart Citations

Comorbidity in Oncology: Modern Challenges and the Search for Ways to Solve the Problem

Drobotun,

Kolotilov,

Konovalenko

et al. 2024

Clin. and prev. med.

View full text Add to dashboard Cite

Introduction. The article is devoted to the current problem of modern oncology – increasing the treatment effectiveness of cancer patients with comorbidities. Comorbidity is accompanied by higher rates of mortality, disability, side effects of treatment, increased use of the patient's body resources, and lower quality of life. The aim of the study. To develop a method of recurrence prevention after bone lesions resection and bone replacement surgery for malignant primary bone tumors, which would ensure a longer duration of the 1st recurrence-free period in patients with comorbidities. Materials and methods. The study included a control group consisting of 27 patients who underwent bone replacement surgery after removal of primary malignant tumors of the pelvis and lower extremities. The study group included 25 patients who underwent biomin bone replacement surgery after removal of malignant primary tumors of the pelvic bones and lower limbs, as well as neuropeptide therapy with the drug dalargin. Results. The obtained data testify to the effectiveness of the proposed method of treatment with the use of dalargin: compaction of the structure of compact and spongy tissues and an increase in their heterogeneity have been established. Under the influence of dalargin, the structure of the interface, characteristic of intact bone tissue, is reorganized, accordingly, the restoration of strength is observed. 12 months after the operation, the bone density in the patients of the main group practically recovered to the values typical for the intact limb (p<0.01). No such recovery was observed in patients of the control group. Within 11 to 23 months, 10 patients of the control group had tumor recurrences. Instead, in the study group, the analysis of the results revealed the following: within 21 months, only 1 patient had a recurrence of the tumor. Conclusions. Neuropeptide Dalargin helps to increase the duration of the 1st relapse-free period in patients with primary malignant bone tumors with polymorbidity. The proposed treatment method with integration into the therapeutic protocol of the neuropeptide dalargin allows to increase the complex therapy effectiveness and improve the prognosis of the course of the disease.

show abstract

Section: рисунок 1 питома вага онкологічних пацієнтів з коморбідністю...unclassified

Section: обговоренняunclassified

See 1 more Smart Citation

Comorbidity in Oncology: Modern Challenges and the Search for Ways to Solve the Problem

Drobotun,

Kolotilov,

Konovalenko

et al. 2024

Clin. and prev. med.

View full text Add to dashboard Cite

show abstract

Nivolumab

2024

Reactions Weekly

View full text Add to dashboard Cite

Multiple Organ Scoring Systems for Predicting In-Hospital Mortality of Sepsis Patients in the Intensive Care Unit

Zhou,

Zhang,

Wang

et al. 2024

Preprint

View full text Add to dashboard Cite

Objective This study aims to comprehensively evaluate the Charlson Comorbidity Index (CCI), Logistic Organ Dysfunction System (LODS) score, Acute Physiology Score III (APS III), Simplified Acute Physiology Score II (SAPS II), and SOFA (Sequential Organ Failure Assessment) in order to provide a more scientifically rigorous and effective tool for predicting mortality risk among sepsis patients in the Intensive Care Unit (ICU). Methods The demographic information and sepsis-related data were extracted from the MIMIC-IV database for patients admitted to the ICU with a diagnosis of sepsis. The predictive performance of CCI, LODS, APS III, SAPS II, and SOFA scoring systems in terms of ICU mortality was evaluated by comparing receiver operating characteristic (ROC) curves. Furthermore, multivariate regression analysis was conducted to identify potential predictors which were subsequently validated using a nomogram. Finally, the dataset was divided into a training set and validation set at a ratio of 7:3 to assess the clinical utility of the prediction model through ROC curves. Results The study enrolled a total of 17,226 patients with a median age of 67.65 (55.79, 78.82) years; among them, males accounted for 57.69%. Within this cohort, a total of 1,115 (6.47%) individuals succumbed during their admission to the ICU. The ROC curve demonstrated that both APS III and LODS score exhibited robust predictive value for ICU mortality. Multivariate regression analysis revealed that CCI, APS III score, LODS score, respiratory rate, body temperature, and race served as potential predictors. The integration of these indicators into a nomogram demonstrated significant clinical relevance, as evidenced by an area under the curve (AUC) of 0.803 in the training set and 0.797 in the validation set. Conclusions Organ failure scores hold significant clinical relevance in predicting mortality among sepsis patients in the ICU. Augmenting predictive accuracy can be achieved by integrating the CCI, APS III score, LODS score, mean respiratory rate, and body temperature during the initial 24 hours following ICU admission.

show abstract

Evaluating the Effectiveness of the Charlson Comorbidity Index in Predicting Immune Checkpoint Inhibitor-Related Adverse Events

Cited by 3 publications

References 16 publications

Comorbidity in Oncology: Modern Challenges and the Search for Ways to Solve the Problem

Comorbidity in Oncology: Modern Challenges and the Search for Ways to Solve the Problem

Nivolumab

Multiple Organ Scoring Systems for Predicting In-Hospital Mortality of Sepsis Patients in the Intensive Care Unit

Contact Info

Product

Resources

About